Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Results 1 - 20 of 55 : 1 2 3 Next »

Recs

0
Member Avatar Jibo999 (< 20) Submitted: 1/20/2014 3:02:49 PM : Outperform Start Price: $1.35 AEZS Score: -21.69

Super rich pipeline

Recs

0
Member Avatar SqwiiTrader (46.73) Submitted: 11/15/2013 2:53:46 PM : Outperform Start Price: $1.66 AEZS Score: -40.56

mako

Recs

0
Member Avatar TerryHoodSr (33.09) Submitted: 7/29/2013 10:57:07 PM : Outperform Start Price: $1.39 AEZS Score: -34.02

growth

Recs

3
Member Avatar zzlangerhans (99.70) Submitted: 3/25/2013 6:44:02 PM : Outperform Start Price: $1.87 AEZS Score: -66.11

Somehow I missed the gap down with the failure of the phase III trial of perifosine in myeloma which I had been predicting for months. I'll try and make up for it by greenthumbing the stock at a despondent low. Now that perifosine is out of the picture, Aeterna has an enterprise value of only 5M despite having cytotoxic LHRH analogue AEZS-108 in advanced clinical trials for endometrial, breast, and prostate cancers. Ozarelix and AEZS-130 have less potential but still add depth to the pipeline. Given Aeterna's history of temporarily resuscitating itself, I think it might be reasonable to grab an initial tranche of shares if the price remains stable under 2.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 11/5/2012 10:28:50 PM : Outperform Start Price: $2.25 AEZS Score: -87.64

Upcoming Clinical trial catalysts.

Recs

0
Member Avatar stainsolution (35.09) Submitted: 4/4/2012 7:12:44 PM : Outperform Start Price: $4.53 AEZS Score: -116.25

Bottom play. Betting on the future pipeline

Recs

0
Member Avatar leelu99 (< 20) Submitted: 4/4/2012 4:51:43 PM : Outperform Start Price: $4.53 AEZS Score: -116.25

Stock history around 1.5+ split at .75.... buy!

Recs

0
Member Avatar TheGreek1966 (< 20) Submitted: 4/3/2012 2:20:25 AM : Outperform Start Price: $4.38 AEZS Score: -113.12

This is a company I have been monitoring for some time. The management team is great and will correct the value lost in no time.

Recs

0
Member Avatar ValueOfTime (95.84) Submitted: 4/2/2012 11:16:16 PM : Outperform Start Price: $4.38 AEZS Score: -113.12

People buy hype. Stock price is low and the only direction hype can go is up for this stock.

Recs

0
Member Avatar Dent001 (67.74) Submitted: 4/2/2012 12:35:05 PM : Outperform Start Price: $4.57 AEZS Score: -113.88

why not

Recs

0
Member Avatar RBuskey106 (40.79) Submitted: 3/14/2012 10:27:15 PM : Outperform Start Price: $10.20 AEZS Score: -129.61

Long term....interesting pipeline

Recs

0
Member Avatar K3VIN0 (29.38) Submitted: 1/8/2012 4:56:09 AM : Outperform Start Price: $9.96 AEZS Score: -142.68

Perifosine is looking good. Pipeline shows potential.

Recs

1
Member Avatar vaderblue (23.54) Submitted: 11/14/2011 7:29:20 PM : Outperform Start Price: $10.02 AEZS Score: -146.24

I am convienced AEZS is on the right track but only time will tell. I am betting on AEZS to succeed. After all the shares are cheap and owning some shares may be a good thing in the long run.

Recs

0
Member Avatar rossklaw (< 20) Submitted: 10/3/2011 11:52:10 PM : Outperform Start Price: $8.46 AEZS Score: -168.60

Pipeline gamble

Recs

0
Member Avatar DBurner (52.60) Submitted: 9/12/2011 12:12:19 AM : Outperform Start Price: $11.28 AEZS Score: -162.26

Deep pipeline and high hopes for perifosene.

Recs

0
Member Avatar Stef100000 (< 20) Submitted: 9/10/2011 9:32:26 PM : Outperform Start Price: $11.28 AEZS Score: -162.26

Test for perifosine is coming out next year big market

Recs

4
Member Avatar TMFUltraLong (99.95) Submitted: 8/9/2011 12:06:53 AM : Outperform Start Price: $9.60 AEZS Score: -161.08

It's a biotech - it will either earn or burn. Based on the research I've done on Aeterna Zentaris and its partnership with Keryx, all signs are pointing that their phase 3 trial will bring a favorable result from the FDA. Aeterna Zentaris has 11 molecules in its pipeline of which 6 are currently in clinical trials. There's plenty of cash here as well, so minimal dilution to shareholders. Fell off a cliff with the rest of the market and down more than 40% in a month. Time to jump aboard on a hopeful dip tomorrow morning.

TMFUltraLong

Recs

0
Member Avatar almostgem (21.94) Submitted: 6/9/2011 2:49:26 PM : Outperform Start Price: $14.10 AEZS Score: -143.84

Cancer drug in the pipeline that has been shown to be successful and is now in Stage III testing. If successful, the stock price should soar. Also look to KERX who has agreements with Aeterna Zentraris to market the drug in US MExico and Canada.
the company also has several other drugs in the pipeline and a drug currently released. Even if the drug is not successful, the company has enough to last at least 2 years at the current burn rate.

Recs

0
Member Avatar HicAZ (20.75) Submitted: 5/20/2011 3:30:59 PM : Outperform Start Price: $13.38 AEZS Score: -138.66

Superb pipeline of drugs in various stages of development and trials.

Recs

0
Member Avatar BACnumber1 (< 20) Submitted: 5/15/2011 1:43:51 AM : Outperform Start Price: $13.74 AEZS Score: -139.44

cheap healthcare!

Results 1 - 20 of 55 : 1 2 3 Next »

Featured Broker Partners


Advertisement